i
Tuberculosis Skin Test and Interferon Gamma Release Assays Usage among Privately Insured Persons in the US
-
6-01-
-
-
Source: Int J Tuberc Lung Dis. 21(6):684-689
[PDF-225.25 KB]
Details:
-
Alternative Title:Int J Tuberc Lung Dis
-
Personal Author:
-
Description:Objective:
Describe tuberculin skin test (TST) and interferon gamma release assays (i.e., QFT and T-Spot) usage among privately insured persons in the US over a 15-year period.
Methods:
We used current procedural terminology (CPT) codes for TST and IGRAs to extract outpatient claims (2000–2014) and determined the usage (claims/100,000). Chi-square test for trend in proportions was used to describe usage trends for select periods.
Results:
TST was the dominant (>80%) test in each year. Guideline publication preceded the assignment of QFT and T-Spot CPT codes by one year (2006 for QFT; 2011 for T-Spot). QFT usage was higher (p<0.01) than T-Spot in each year. The average annual increase in the use of QFT was higher than that of T-Spot (35/100,000 vs. 3.8/100,000), and more so when the analytic period was 2011–2014 (65/100,000 vs. 38/100,000). However, during that four-year period (2011–2014), TST use trended downward––average annual decrease of 28/100,000. The annual proportion of enrollees tested ranged from 1.1%–1.5%.
Conclusions:
These results suggest a gradual shift from the use of TST to the newer IGRAs. Future studies can assess the extent, if any, to which the shift from the use of TST to IGRAs evolve over time.
-
Subjects:
-
Source:
-
Pubmed ID:28351463
-
Pubmed Central ID:PMC9469180
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
